ALK-001 is named as a drug or biological intervention in 3 clinical trials in our USA trial register, 1 of which is recruiting. The lead sponsor is Alkeus Pharmaceuticals, Inc.. Registered phases: Phase 2 and Phase 3. Conditions studied include Stargardt Disease; Stargardt Macular Degeneration; Stargardt Macular Dystrophy.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07419334 | Study of ALK-001 on the Progression of Stargardt Disease (ClinicalTrials.gov ↗) Stargardt Disease |
Phase 3 | Recruiting |
| NCT02402660 | Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy |
Phase 2 | Active, closed |
| NCT04239625 | Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) (ClinicalTrials.gov ↗) Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy |
Phase 2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Stargardt Disease | 3 |
| Stargardt Macular Degeneration | 2 |
| Stargardt Macular Dystrophy | 2 |
| Autosomal Recessive Stargardt Disease 1 (ABCA4-related) | 2 |
| Lead sponsor | Trials |
|---|---|
| Alkeus Pharmaceuticals, Inc. | 3 |
| Register | ALK-001 trials |
|---|---|
| Clinical trials in USA | 3 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how ALK-001 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists ALK-001 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.